WhiteSwell
Eamon Brady is currently the CEO of WhiteSwell, a company focused on advancing treatment for acute decompensated heart failure. Prior to this, Brady was the CEO and Co-Founder of Neuravi before it was acquired by Johnson & Johnson, where Eamon then served as the CEO of the Neuravi division. With previous experience in companies like Abbott Vascular and MedNova Ltd, Brady has a strong background in R&D and new ventures within the medical industry.
This person is not in any offices
WhiteSwell
WhiteSwell is a science-driven company dedicated to improving treatment of acute decompensated heart failure (ADHF), a primary cause of repeat hospitalization and emergency room visits. The company is pioneering a minimally invasive catheter-based approach designed to more efficiently remove excess interstitial fluid in patients with ADHF by enhancing the natural fluid removal process of the lymphatic system. For more information visit www.whiteswell.com.